Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valiltramiprosate (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
Acronyms APOLLOE4
Sponsors Alzheon

Most Recent Events

08 Sep 2026 Results published in the Media Release
06 Jul 2026 Results presented in an Alzheon media release.
06 Jul 2026 According to an Alzheon media release, data from the study will presented at the 2026 Alzheimer's Association International Conference (AAIC) in London

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com